Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Yin, Hang; Lü, Kai; Qiao, Wenbo; Zhang, Haiyang; Sun, Di; You, Qingshan

doi:10.7314/apjcp.2014.15.4.1597

Cited by 6 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The grade 3-4 adverse reaction reached as high as 53.8%, especially thrombocytopenia, oral mucositis, loss of appetite and fatigue, but patients could tolerate it. The other adverse reactions were non significantly difference between study and control group such as the transaminase was increased by 34.6% and bilirubin was increased by 11.5% after liver radiotherapy , which was similar with Yin ( 2014).…”

Section: Discussionsupporting

confidence: 74%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil. Materials and Methods: Eligible patients were randomly assigned to a study group treated with dose-dense cisplatin plus fluorouracil following selective radiotherapy and a control group receiving traditional cisplatin plus fluorouracil following selective radiotherapy according to a 1:1 distribution using a digital random table method. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, relapse or progression rate in the radiation field and treatment toxicity. Results: Of 52 patients in the study group, 20 cases underwent radiotherapy., while in the control group of 51 patients, 16 underwent radiotherapy. The median PFS, median OS, survival rates in 1, 2 and 3 years in study and control group were 20.9 vs 12.7months, 28.3 vs 18.8months, 85.2%vs 65.9%, 62.2% vs 18.3%, and 36.6%vs 5.2% (p values of 0.00, 0.00, 0.04, 0.00 and 0.00, respectively). Subgroup analysis showed that the median OS and survival rates of 1, 2, 3 years for patients undergoing radiotherapy in the study group better than that in control group( 43.2vs24.1 months, 94.1% vs 86.7%, 82.4% vs 43.3%, 64.7% vs 17.3%, (p=0.00, 0.57, 0.04 and 0.01, respectively). The complete response rate, objective response rate after chemotherapy and three months after radiotherapy, relapse or progression rate in radiation field in study group and in control group were 19.2% vs 3.9%, 86.5% vs 56.9%, 85% vs 50%, 95% vs 81.3% and 41.3% vs 66.7% (p =0.03, 0.00, 0.03,0.30, 0.01 respectively). The grade 3-4 acute adverse reactions in the study group were significantly higher than in the control group (53.8% vs 9.8%, p=0.00). Conclusions: The survival of patients benefits from selective radiotherapy after distant metastasis of NPC treated with dose-dense cisplatin plus fluorouracil.

show abstract

Section: Discussionsupporting

confidence: 74%

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Bu¹,

Cheng²,

Gao³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…In an interesting study (Yin et al, 2014) treated 19 colorectal liver metastases patients using whole liver radiotherapy with boost on massive leasion and chemotherapy and 100% patients showed decreased pain, as measured by a reduced need for analgesics (median survival time was 19 months, 1-and 2-year overall survival rates were 78.3% and 14.3%). The mean number of liver lesions treated per patient was 3 (range, 2 to 6) and the maximal diameter of all the lesions was 7 cm (range, 6 to 12 cm).…”

Section: Discussionmentioning

confidence: 99%

Whole Liver Palliative Radiotherapy for Patients with Massive Liver Metastases

Wolny‐Rokicka¹,

Lipiński²,

Wydmański³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The purpose of this retrospectively study was to examine the effectiveness and tolerability of a radiotherapy technique for the palliation of symptomatic liver metastases. Materials and Methods: Twentyseven patients with liver metastases were enrolled and received targeted whole liver irradiation consisting of mean 1, 8 Gy in five to twelve fractions to a total mean dose 17Gy. Symptoms at baseline were hepatic pain (26 patients), lost of weight (6), lack of appetite (2), and night sweats (1). Seventeen patients (63%) had failed previous treatment with chemotherapy and/or high-dose steroids. Results: Individual symptom response rates were 100% at 4 weeks. Partial or complete global symptomatic responses were noted in 11 patients (40%) after 2 months. After 3 months, 8 patients (28%) reported loss of pain. The treatment was well tolerated with one patient (3%) experiencing grade 3 toxicity (one vomiting and one diarrhoea). Overall the median survival time was 4.9 months (range 1 -14 months). One year survival was 39%. Conclusions: This is simple and well-tolerated treatment but to achieve good palliation effects we should carefully selected patients whose conventional treatment does not bring good analgesic control.

show abstract

“…28 WLRT/PLRT 10 Gy/2 # 54% partial or complete symptomatic response 2 patients with Grade 3 vomiting and diarrhoea Yin et al . [35] 2014 CRC 19 WLRT + tumor boost + concurrent chemotherapy 53.4 Gy (including boost)/# NR 52.6% overall response 2 patients with Grade 3 elevated bilirubin Edyta et al . [34] 2015 the various modalities are needed to elucidate comparative long-term outcomes of RT specifically.…”

Section: Treatment Dose/fractionation (#) Outcome Toxicitiesmentioning

confidence: 99%

Can radiotherapy finally “go live” in the management of liver metastases?

John¹,

Ho²,

Appalanaido³

et al. 2020

View full text Add to dashboard Cite

Liver metastases can present synchronously or at different time points. While systemic therapy continues to be the mainstay of treatment for patients with liver metastases, it is unlikely to completely eradicate the disease. Surgical "metastectomy" for patients with limited metastatic burden, particularly from colorectal cancers, has been shown to improve survival. However, owing to medical co-morbidities or tumour location, not all patients are eligible for surgical resection. In recent years, there has been an increase in the use of non-surgical techniques, including high dose radiation using stereotactic body radiotherapy, or brachytherapy, to ablate liver metastases. The purpose of this narrative review is to describe the role of radiotherapy in the management of liver metastases, both for local ablation and symptom palliation. We will elaborate on the techniques used, patient selection process, expected outcomes and toxicities based on the current literature.

show abstract

Whole-liver Radiotherapy Concurrent with Chemotherapy as a Palliative Treatment for Colorectal Patients with Massive and Multiple Liver Metastases: a Retrospective Study

Cited by 6 publications

References 38 publications

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

Whole Liver Palliative Radiotherapy for Patients with Massive Liver Metastases

Can radiotherapy finally “go live” in the management of liver metastases?

Contact Info

Product

Resources

About